**SEER Program Coding and Staging Manual 2022 - Summary of Changes**
This table lists the changes in the 2022 manual by page number.

| Page | Section | Data Item | Change | Notes/Comments |
|------|---------|-----------|--------|----------------|
| 1 | Preface | Summary of Changes | Listing of major changes updated. | Revised the section with the list of major changes including additions, deletions, and modifications made to the 2022 manual and appendices. |
| 2 | Preface | 2022 Changes | Listing of additional 2022 changes updated. | Revised the list of 2022 changes relating to cancer coding and staging. |
| 3 | Introduction | Submitting Questions | Text added. | Submit technical questions, suggestions, and revisions related to this manual to Ask A SEER Registrar on the SEER website. An appointed staff member from each SEER core registry may also submit technical questions to NCI SEER inquiry system using the web-based SINQ system. Updates to this manual identified after publication will be found in SINQ under the category of 'Updates to current manual' until a subsequent revision of this manual is issued. |
| 3 | Preface | Transmission Instructions for Dates | Text deleted. | Deleted sentence: Date data items are fixed-length and left-justified. |
| 6 | Reportability | Reportable Diagnosis List | Item 1.a.i and ii added. | i.  Clear cell papillary renal cell carcinoma (8323/3) is reportable<br>ii.  Low-grade appendiceal mucinous neoplasm (LAMN) is reportable<br><br>Subsequent items were renumbered. |
| 6 | Reportability | Reportable Diagnosis List | Item 1.a.iv revised. | iv. **All** GIST tumors, *except* for those stated to be benign, are reportable as of 01/01/2021. The behavior code is /3 in ICD-O-3.2. |
| 7 | Reportability | Reportable Diagnosis List | Item 1.b.iv, v, and vi added. | iv. Colon atypical hyperplasia<br>v. High grade dysplasia in colorectal and esophageal primary sites<br>vi. Adenocarcinoma in situ, HPV associated (8483/2)(C53) |
| 8 | Reportability | Reportable Diagnosis List | Item 1.b edited. | Added statement at end of section:<br>Refer to Appendix E.2 for non-reportable examples. |

SEER Program Coding and Staging Manual 2022 - Summary of Changes
This table lists the changes in the 2022 manual by page number.

| Page | Section | Data Item | Change | Notes/Comments |
|------|---------|-----------|--------|----------------|
| 10 | Reportability | Ambiguous Terminology | Text revised and exception added. | **Cytology** Do **not** accession a case based ONLY on **suspicious** cytology. Follow back on cytology diagnoses using ambiguous terminology is strongly recommended. Accession the case when a reportable diagnosis is confirmed later. The date of diagnosis is the date of the suspicious cytology.***Exception:*** This is a change to previous instructions. The date of a suspicious cytology may be used as the date of diagnosis when a definitive diagnosis follows the suspicious cytology. See Date of Diagnosis for more information. |
| 11 | Reportability | Ambiguous Terminology | Ambiguous Terms for Reportability section revised. | Added so section: Use **all available information first and seek clarification** from clinicians whenever possible. Added text under the list of Ambiguous Terms for Reportability regarding equivalent terms "Diagnostic for," "Not diagnostic for," and "Differential diagnoses."  See manual for listing of terms. Added the last paragraph to the section: If there is no information to the contrary, report a case described as "malignant until proven otherwise." The patient should have further work up to prove or disprove the findings. When additional information becomes available, update as necessary.  Use text fields to describe the details. |
| 15 | Changing Information on the Abstract | | Item 4 example dates revised. | **When the date of diagnosis is confirmed in retrospect to be earlier than the original date abstracted** *Example*: Patient has surgery for a benign argentaffin carcinoid (8240/1) of the sigmoid colon in May 2021. In January 2022, the patient is admitted with widespread metastasis consistent with malignant argentaffin carcinoid. The registrar accessions the malignant argentaffin carcinoid as a 2022 diagnosis. Two months later, the pathologist reviews the slides from the May 2021 surgery and concludes that the carcinoid diagnosed in 2021 was malignant. Change the date of diagnosis to May 2021 and histology to 8241 and the behavior code to malignant (/3). |

SEER Program Coding and Staging Manual 2022 - Summary of Changes
This table lists the changes in the 2022 manual by page number.

| Page | Section | Data Item | Change | Notes/Comments |
|---|---|---|---|---|
| 16 | Determining Multiple Primaries | Hematopoietic and Lymphoid Neoplasms | Tense changed. | Updated wording in this section to past tense. Updates to the *Hematopoietic and Lymphoid Neoplasm Coding Manual* and *Database* were made for 2021 cases. The updates reflect changes based on ICD-O-3.2. Apply the Multiple Primary Rules in the *Hematopoietic and Lymphoid Neoplasm Coding Manual* and *Database.* |
| 18 | Section I: Basic Record Identification | SEER Participant | SEER registries added. | Updated Core registries tables and added table of Support registries.  See manual. |
| 23 | Section I: Basic Record Identification | NAACCR Record Version | Data item added. | See manual. |
| 67 | Section III: Demographic Information | Race 1, 2, 3, 4, 5 | Code modified. | Code description for code 03 modified to:<br>American Indian, Aleutian, or Alaska Native (includes all indigenous populations of the western hemisphere) |
| 80 | Section III: Demographic Information | Tobacco Use Smoking Status | Data item added. | See manual. |
| 84 | Section IV: Description of this Neoplasm | Date of Diagnosis | Coding Instruction 1 exception deleted. | Deleted:<br>*Exception:* Do not use the date of diagnosis from a cytology report using ambiguous terminology. See Coding Instruction #5 below. |
| 84 | Section IV: Description of this Neoplasm | Date of Diagnosis | Coding Instruction 1 example dates updated. | *Example:* Area of microcalcifications in breast suspicious for malignancy on 02/13/2022. Biopsy positive for ductal carcinoma on 02/28/2022. The date of diagnosis 02/13/2022. |
| 84 | Section IV: Description of this Neoplasm | Date of Diagnosis | Coding Instruction 3 example 1 dates updated. | Renamed example to Example 1 and updated dates:<br>*Example 1:* On May 15, 2022, physician states that patient has lung cancer based on clinical findings. The patient has a positive biopsy of the lung in June 3, 2022. The date of diagnosis remains May 15, 2022. |

SEER Program Coding and Staging Manual 2022 - Summary of Changes
This table lists the changes in the 2022 manual by page number.

| Page | Section | Data Item | Change | Notes/Comments |
|---|---|---|---|---|
| 84 | Section IV: Description of this Neoplasm | Date of Diagnosis | Coding Instruction 3 example 2 and note added. | Added second example:<br>**Example 2**: Radiologist reports Liver Imaging Reporting and Data System (LI-RADS) Category 5 on imaging. Later biopsy confirms hepatocellular carcinoma (HCC). Record date of diagnosis as date of LI-RADS imaging.<br><br>**Note**: Appendix E in the 2022 SEER Program Manual lists which PI-RADS, BI-RADS, and LI-RAD are reportable versus non-reportable. If reportable, use the date of the procedure as the date of diagnosis when this is the earliest date and there is no information to dispute the imaging findings. |
| 84 | Section IV: Description of this Neoplasm | Date of Diagnosis | Coding Instruction 5 and note 1 revised; example added. | 5. Use the date of suspicious cytology when the diagnosis is proven by subsequent biopsy, excision, or other means<br><br>**Example:** Cytology suspicious for malignancy 01/12/2022. Diagnosis of carcinoma per biopsy on 02/06/2022. Record 01/12/2022 as the date of diagnosis.<br><br>**Note 1:** "Suspicious" cytology means that the diagnosis is preceded by an ambiguous term such as apparently, appears, compatible with, etc. |
| 85 | Section IV: Description of this Neoplasm | Date of Diagnosis | Coding Instructions 6, 9, and Cases Diagnosed Before Birth examples revised. | Updated dates to 2022 in the examples. |
| 88 | Section IV: Description of this Neoplasm | Tumor Record Number | Data item added. | See manual. |
| 91 | Section IV: Description of this Neoplasm | Sequence Number--Central | Coding Instruction 6 example revised | Updated date to 2022 in the example under Non-Malignant Coding Instructions. |

SEER Program Coding and Staging Manual 2022 - Summary of Changes
This table lists the changes in the 2022 manual by page number.

| Page | Section | Data Item | Change | Notes/Comments |
|---|---|---|---|---|
| 92 | Section IV: Description of this Neoplasm | Primary Site | Section added | **Resources for Coding Primary Site for Solid Tumors, in priority order**1. ICD-O2. SEER Program Manual    a. Including Coding Guidelines in Appendix C3. Solid Tumor Rules |
| 93 | Section IV: Description of this Neoplasm | Primary Site | Coding Instruction 3 added. | 3. Do *not* adjust the primary site code to fit staging or any other data items<br><br>Subsequent instructions renumbered. |
| 94 | Section IV: Description of this Neoplasm | Primary Site | Coding Instruction 8.a and note added. | 8. Code the primary site, not the metastatic site. If a tumor is metastatic and the primary site is unknown, code the primary site as unknown (C809).<br>a. Code primary site using results of the molecular test CancerTYPE ID only when there is no other information about the primary site. Document in the text that the site is solely based on results from CancerTYPE ID molecular testing.<br>*Note:* CancerTYPE ID tests are a standardized molecular method of determining primary site in tumors initially identified in a metastatic site. The use of CancerTYPE ID to determine primary site is not yet a standard practice and has not received FDA clearance. |
| 95 | Section IV: Description of this Neoplasm | Primary Site | Coding Instruction 15 table revised. | Added to the table in instruction #15:<br>Back of tongue C019<br>Interarytenoid space C329<br>Intracranial C719<br>Porta hepatis C220<br>True vocal folds C320 |
| 98 | Section IV: Description of this Neoplasm | Laterality | Note added. | Added note to section Sites for Which Laterality Codes Must Be Recorded:<br>*Note:* Laterality will be automatically coded to 0 in SEER*DMS for sites not listed in the table below. |
| 99 | Section IV: Description of this Neoplasm | Laterality | Table edited. | Added C444, skin of scalp and neck, to the table Sites for Which Laterality Codes Must Be Recorded<br><br>Revised C445 to Skin of trunk |

SEER Program Coding and Staging Manual 2022 - Summary of Changes
This table lists the changes in the 2022 manual by page number.

| Page | Section | Data Item | Change | Notes/Comments |
|---|---|---|---|---|
| 104 | Section IV: Description of this Neoplasm | Histologic Type ICD-O-3 | Text added. | Added under section **ICD-O-3.2:** See the NAACCR website for additional updates for 2022. |
| 104 | Section IV: Description of this Neoplasm | Histologic Type ICD-O-3 | Text added. | Added under section **Histology Coding for Solid Tumors**Refer to the most current Solid Tumor Rules for histology code changes.1. Beginning with cases diagnosed 01/01/2022 forward, p16 test results can be used to code squamous cell carcinoma, HPV positive (8085) and squamous cell carcinoma, HPV negative (8086). 2. Beginning 1/1/2022, non-keratinizing squamous cell carcinoma, HPV positive is coded 8085 for sites listed in Head and Neck Solid Tumor Rules Table 5 only. A diagnosis of non-keratinizing squamous cell carcinoma, NOS is coded 8072.3. Beginning 1/1/2022, keratinizing squamous cell carcinoma, HPV negative is coded 8086 for sites listed in Head and Neck Solid Tumor Rules Table 5 only. A diagnosis of keratinizing squamous cell carcinoma, NOS is coded 8071.4. Clear cell papillary renal cell carcinoma is coded 8323/3. The 2016 WHO Classification of Tumors of the Urinary System and Male Genital Organs, 4th Edition, has reclassified this histology as a /1 because it is low nuclear grade and is now thought to be a neoplasia. This change has not yet been implemented and it remains reportable as behavior /3. |
| 106 | Section IV: Description of this Neoplasm | Behavior Code | Coding Instruction added. | Added section **General** Code behavior prior to neoadjuvant therapy when given. |
| 106 | Section IV: Description of this Neoplasm | Behavior Code | Example in second paragraph revised. | Added a sentence to the example under **Metastatic or Non-primary Sites**: *Example*: Adenocarcinoma in situ with lymph nodes positive for malignancy. Code the behavior as malignant (/3). When the invasive component cannot be found and there are positive lymph nodes, assign behavior /3 based on the positive lymph nodes. |
| 113 | Section IV: Description of this Neoplasm | Tumor Size--Clinical | Introductory paragraph revised. | Added language to first paragraph, second sentence: Clinical classification is composed of diagnostic workup prior to first treatment, including physical examination, imaging, pathological findings (gross description and microscopic measurements most likely from a biopsy that did not remove the entire lesion), and surgical exploration without resection. |

This table lists the changes in the 2022 manual by page number.

| Page | Section | Data Item | Change | Notes/Comments |
|---|---|---|---|---|
| 113 | Section IV: Description of this Neoplasm | Tumor Size--Clinical | Coding Instruction 2.b.i example revised. | Revised the second example found under the note in 2.b.i:<br>*Example:* A breast biopsy revealed a 1.3 cm ductal carcinoma. There was no residual carcinoma found in the partial mastectomy specimen. The biopsy removed the whole tumor which makes it an excisional biopsy. Code the clinical tumor size as 999 and the path tumor size as 013. |
| 114 | Section IV: Description of this Neoplasm | Tumor Size--Clinical | Coding Instruction 3 added. | 3. Use clinical history on a pathology report for clinical tumor size when that is the only information available to code clinical tumor size. Use text field to record the details.Subsequent instructions renumbered. |
| 115 | Section IV: Description of this Neoplasm | Tumor Size--Clinical | Coding Instruction 9 added. | 9.  Do *not* use endometrial ultrasound reporting endometrial stripe or thickening because this does *not* represent clinical tumor size. |
| 116 | Section IV: Description of this Neoplasm | Tumor Size--Clinical | Coding Instruction 22.b revised. | 22.  Assign code **000** when<br>a. Schema is Cervical Lymph Nodes and Unknown Primary 00060<br>b. EOD Primary Tumor is coded 800 (No evidence of primary tumor) for any schema except for those listed in Coding Instruction 24 |
| 117 | Section IV: Description of this Neoplasm | Tumor Size--Clinical | Coding Instruction 24.d edited. | d. Lymphoma  00790 |
| 120 | Section IV: Description of this Neoplasm | Tumor Size--Pathologic | Coding Instruction 1 example revised. | *Example:*  A breast biopsy revealed a 1.3 cm ductal carcinoma. There was no residual carcinoma found in the partial mastectomy specimen. The biopsy removed the whole tumor which makes it an excisional biopsy. Code the clinical tumor size as 999 and the path tumor size as 013. |
| 122 | Section IV: Description of this Neoplasm | Tumor Size--Pathologic | Coding Instruction 20.a.i added and 2.c revised. | 20. Assign code 000 when<br>a. No residual tumor is found<br>i. Neoadjuvant therapy has been administered and the resection shows no residual tumor<br>b. Schema is Cervical Lymph Nodes and Unknown Primary 00060<br>c. EOD Primary Tumor is coded 800 (No evidence of primary tumor) for any schema except for those listed in Coding Instruction 22 |

SEER Program Coding and Staging Manual 2022 - Summary of Changes
This table lists the changes in the 2022 manual by page number.

| Page | Section | Data Item | Change | Notes/Comments |
|---|---|---|---|---|
| 123 | Section IV: Description of this Neoplasm | Tumor Size--Pathologic | Coding Instruction 22.f.iv edited. | iv. Lymphoma  00790 |
| 126 | Section V: Stage of Disease at Diagnosis | Introductory section | Note added. | Added note to section introduction:<br>***Note:*** There are no specific instructions for pathology-only cases. Assign 9s or the appropriate "unknown" code when abstracting stage and related data items from pathology reports or HL-7 reports only and information is not provided. |
| 128 | Section V: Stage of Disease at Diagnosis | Extent of Disease Primary Tumor | Text edited. | Deleted 2018 from text referring to EOD data collection system. |
| 129 | Section V: Stage of Disease at Diagnosis | Extent of Disease Regional Nodes | Text edited. | Deleted 2018 from text referring to EOD data collection system. |
| 130 | Section V: Stage of Disease at Diagnosis | Extent of Disease Metastases | Text edited. | Deleted 2018 from text referring to EOD data collection system. |
| 135 | Section VI: Stage-related Data Items | Stage-related Data Items | Text revised. | Nine data items are presented in this section. See the Site-specific Data Item (SSDI) Manual for data items not included in this section. |

SEER Program Coding and Staging Manual 2022 - Summary of Changes
This table lists the changes in the 2022 manual by page number.

| Page | Section | Data Item | Change | Notes/Comments |
|---|---|---|---|---|
| 136 | Section VI: Stage-related Data Items | Lymphovascular Invasion | Code Descriptions edited. | Code descriptions modified for codes 1, 2, 3, and 4.<br>1 Lymphovascular Invasion Present/Identified (NOT used for thyroid and adrenal)<br>2 Lymphatic and small vessel invasion only (L)<br>  OR<br>  Lymphatic invasion only (thyroid and adrenal only)<br>3 Venous (large vessel) invasion only (V)<br>  OR<br>  Angioinvasion (thyroid and adrenal only)<br>4 BOTH lymphatic and small vessel AND venous (large vessel) invasion<br>  OR<br>  BOTH lymphatic AND angioinvasion (thyroid and adrenal only) |
| 136 | Section VI: Stage-related Data Items | Lymphovascular Invasion | Coding Instruction 2 added. | 2. Code lymphovascular invasion to 0, 2, 3, 4, or 9 for the following Schema IDs<br>Thyroid  00730<br>Thyroid Medullary  00740<br>Adrenal Gland  00760 |
| 137 | Section VI: Stage-related Data Items | Lymphovascular Invasion | Coding Instruction 8.a.vii added. | vii.  Lymphovascular space invasion |
| 138 | Section VI: Stage-related Data Items | Lymphovascular Invasion | Coding instruction 9.b added. | b. For non-malignant brain (intracranial) and CNS tumors |
| 139 | Section VI: Stage-related Data Items | Macroscopic Evaluation of the Mesorectum | Data item added. | See manual. |
| 140 | Section VI: Stage-related Data Items | Mets at Diagnosis--Bone | Coding Instruction 1.d revised. | d. Code this data item for all solid tumor schemas (including Kaposi Sarcoma and Ill-Defined Other [includes unknown primary site]) and the following Hematopoietic schemas except as noted in 2.c. and 2.d. |

SEER Program Coding and Staging Manual 2022 - Summary of Changes
This table lists the changes in the 2022 manual by page number.

| Page | Section | Data Item | Change | Notes/Comments |
|---|---|---|---|---|
| 140 | Section VI: Stage-related Data Items | Mets at Diagnosis--Bone | Coding Instruction 1.d.ii edited and I.d.vi added. | i. Lymphoma Ocular Adnexa  00710<br>ii. Lymphoma  00790<br>iii. Lymphoma-CLL/SLL  00795<br>iv. Mycosis Fungoides (MF)  00811<br>v. Primary Cutaneous Lymphoma (excluding MF and SS)  00812<br>vi. HemeRetic 00830 (excluding primary sites C420, C421, C423, C424) |
| 141 | Section VI: Stage-related Data Items | Mets at Diagnosis--Bone | Coding Instruction 2.c.i revised. | Revised the coding instruction for assigning code 8 (deleted C770-C779):<br>i. Any case coded to primary site C420, C421, C423, or C424 |
| 142 | Section VI: Stage-related Data Items | Mets at Diagnosis--Brain | Coding Instruction 1.d revised. | d. Code this data item for all solid tumor schemas (including Kaposi Sarcoma and Ill-Defined Other [includes unknown primary site]) and the following Hematopoietic schemas except as noted in 2.c. and 2.d. |
| 142 | Section VI: Stage-related Data Items | Mets at Diagnosis--Brain | Coding Instruction 1.d.ii edited and I.d.vi added. | i. Lymphoma Ocular Adnexa  00710<br>ii. Lymphoma  00790<br>iii. Lymphoma-CLL/SLL  00795<br>iv. Mycosis Fungoides (MF)  00811<br>v. Primary Cutaneous Lymphoma (excluding MF and SS)  00812<br>vi. HemeRetic 00830 (excluding primary sites C420, C421, C423, C424) |
| 143 | Section VI: Stage-related Data Items | Mets at Diagnosis--Brain | Coding Instruction 2.c.i revised. | Revised the coding instruction for assigning code 8 (deleted C770-C779):<br>i. Any case coded to primary site C420, C421, C423, or C424 |
| 144 | Section VI: Stage-related Data Items | Mets at Diagnosis--Liver | Coding Instruction 1.d revised. | d. Code this data item for all solid tumor schemas (including Kaposi Sarcoma and Ill-Defined Other [includes unknown primary site]) and the following Hematopoietic schemas except as noted in 2.c. and 2.d. |
| 144 | Section VI: Stage-related Data Items | Mets at Diagnosis--Liver | Coding Instruction 1.d.ii edited and I.d.vi added. | i. Lymphoma Ocular Adnexa  00710<br>ii. Lymphoma  00790<br>iii. Lymphoma-CLL/SLL  00795<br>iv. Mycosis Fungoides (MF)  00811<br>v. Primary Cutaneous Lymphoma (excluding MF and SS)  00812<br>vi. HemeRetic 00830 (excluding primary sites C420, C421, C423, C424) |

SEER Program Coding and Staging Manual 2022 - Summary of Changes
This table lists the changes in the 2022 manual by page number.

| Page | Section | Data Item | Change | Notes/Comments |
|------|---------|-----------|--------|----------------|
| 145 | Section VI: Stage-related Data Items | Mets at Diagnosis--Liver | Coding Instruction 2.c.i revised. | Revised the coding instruction for assigning code 8 (deleted C770-C779):i. Any case coded to primary site C420, C421, C423, or C424 |
| 146 | Section VI: Stage-related Data Items | Mets at Diagnosis--Lung | Coding Instruction 1.d revised. | d. Code this data item for all solid tumor schemas (including Kaposi Sarcoma and Ill-Defined Other [includes unknown primary site]) and the following Hematopoietic schemas except as noted in 2.c. and 2.d. |
| 146 | Section VI: Stage-related Data Items | Mets at Diagnosis--Lung | Coding Instruction 1.d.ii edited and I.d.vi added. | i. Lymphoma Ocular Adnexa  00710<br>ii. Lymphoma  00790<br>iii. Lymphoma-CLL/SLL  00795<br>iv. Mycosis Fungoides (MF)  00811<br>v. Primary Cutaneous Lymphoma (excluding MF and SS)  00812<br>vi. HemeRetic 00830 (excluding primary sites C420, C421, C423, C424) |
| 147 | Section VI: Stage-related Data Items | Mets at Diagnosis--Lung | Coding Instruction 2.c.i revised. | Revised the coding instruction for assigning code 8 (deleted C770-C779):<br>i. Any case coded to primary site C420, C421, C423, or C424 |
| 148 | Section VI: Stage-related Data Items | Mets at Diagnosis--Distant Lymph Node(s) | Coding Instruction 1.e revised. | d. Code this data item for all solid tumor schemas (including Kaposi Sarcoma and Ill-Defined Other [includes unknown primary site]) and the following Hematopoietic schemas except as noted in 2.c. and 2.d. |
| 148 | Section VI: Stage-related Data Items | Mets at Diagnosis--Distant Lymph Node(s) | Coding Instruction 1.e.ii edited and I.e.vi added. | i. Lymphoma Ocular Adnexa  00710<br>ii. Lymphoma  00790 (excluding primary sites C770-C779; see 2.c.)<br>iii. Lymphoma-CLL/SLL  00795 (excluding primary sites C770-C779; see 2.c.)<br>iv. Mycosis Fungoides (MF)  00811<br>v. Primary Cutaneous Lymphoma (excluding MF and SS)  00812<br>vi. HemeRetic 00830 (excluding primary sites C420, C421, C423, C424, see 2.c.) |
| 150 | Section VI: Stage-related Data Items | Mets at Diagnosis--Other | Coding Instruction 1.d revised. | d. Code this data item for all solid tumor schemas (including Kaposi Sarcoma and Ill-Defined Other [includes unknown primary site]) and the following Hematopoietic schemas except as noted in 2.d. and 2.e. |

SEER Program Coding and Staging Manual 2022 - Summary of Changes
This table lists the changes in the 2022 manual by page number.

| Page | Section | Data Item | Change | Notes/Comments |
|------|---------|-----------|--------|----------------|
| 150 | Section VI: Stage-related Data Items | Mets at Diagnosis--Other | Coding Instruction 1.d.ii and iii revised and I.d.vi added. | i. Lymphoma Ocular Adnexa  00710<br>ii. Lymphoma  00790 (see 2.d.)<br>iii. Lymphoma-CLL/SLL  00795 (see 2.d.)<br>iv. Mycosis Fungoides (MF)  00811<br>v. Primary Cutaneous Lymphoma (excluding MF and SS)  00812<br>vi. HemeRetic 00830 (excluding primary sites C420, C421, C423, C424, see 2.d.) |
| 151 | Section VI: Stage-related Data Items | Mets at Diagnosis--Other | Coding Instruction 2.d.i revised. | Revised the coding instruction for assigning code 8 (deleted C770-C779):<br>i. Any case coded to primary site C420, C421, C423, or C424 |
| 154 | Section VI: Stage-related Data Items | Additional Stage-related Data Items | Introductory text revised. | Revised introductory paragraphs to update information.  See manual. |
| 154 | Section VI: Stage-related Data Items | Additional Stage-related Data Items | Table 3 edited. | Updated Table 3 to:  Site-specific Data Items Implemented in 2022.<br>Added note:<br>*Note:*  The new data items are collected by SEER from CoC-accredited hospitals except Derived Rai Stage. |
| 155 | Section VI: Stage-related Data Items | Additional Stage-related Data Items | Table 4 added. | Added Table 4: Additional Site-specific Data Items Required for Transmission.<br>This replaces Table 4 in the previous manual: Table 4: Site-specific Data Items Required for Staging. |
| 163 | Section VII: First Course of Therapy | Date Therapy Initiated | Coding Instruction 3 example revised. | Updated dates to 2022 in the example. |

SEER Program Coding and Staging Manual 2022 - Summary of Changes
This table lists the changes in the 2022 manual by page number.

| Page | Section | Data Item | Change | Notes/Comments |
|------|---------|-----------|--------|----------------|
| 172 | Section VII: First Course of Therapy | Surgery of Primary Site | Coding Instruction 6 revised. | 6. Assign the code that reflects the **cumulative effect** of all surgeries to the primary site.<br>***Example:*** The patient underwent a partial mastectomy and sentinel lymph node biopsy, followed by an axillary lymph node dissection for the first right breast primary in 2011. The separate 2020 right breast primary was treated with a total mastectomy and removal of one involved axillary lymph node. The operative report only refers to this as a non-sentinel lymph node, with no mention of other axillary findings. Cumulatively, this patient has undergone a modified radical mastectomy since there were likely no remaining axillary lymph nodes. For the 2020 primary, code the cumulative effect of the surgery done in 2011 plus the surgery performed in 2020. Use text fields on both abstracts to record the details. |
| 176 | Section VII: First Course of Therapy | Scope of Regional Lymph Node Surgery | Coding Instruction 13.a.ii revised and 13.a.iv, v. and vi added. | a. Assign code 9 for<br>i. Any case coded to primary site: C420, C421, C423, C424, C589, C700-C709, C710-C729, C751-C753, C761-C768, C770-C779, or C809<br>ii. Lymphoma  00790<br>iii. Lymphoma-CLL/SLL  00795<br>iv. Plasma Cell Disorders (excluding histology 9734/3)  00822<br>v. HemeRetic 00830 (excluding primary sites C420, C421, C423, C424)<br>vi. Ill-Defined/Other 99999 |
| 177 | Section VII: First Course of Therapy | Scope of Regional Lymph Node Surgery | Coding Instruction SLNBx 3.b edited. | Deleted 'Lymph' in data item names:<br>Regional Nodes Examined and Regional Nodes Positive |
| 180 | Section VII: First Course of Therapy | Sentinel Lymph Nodes Examined | Coding Instructions 2 and 5 edited. | Deleted 'Lymph in data item names:<br>Regional Nodes Examined and Regional Nodes Positive |
| 181 | Section VII: First Course of Therapy | Sentinel Lymph Nodes Positive | Coding Instructions 2, 4, and 5.a edited. | Deleted 'Lymph in data item names:<br>Regional Nodes Examined and Regional Nodes Positive |

SEER Program Coding and Staging Manual 2022 - Summary of Changes
This table lists the changes in the 2022 manual by page number.

| Page | Section | Data Item | Change | Notes/Comments |
|---|---|---|---|---|
| 183 | Section VII: First Course of Therapy | Date of Regional Lymph Node Dissection | Introductory text edited. | Deleted 'effective 01/01/2018' from first paragraph. |
| 183 | Section VII: First Course of Therapy | Date of Regional Lymph Node Dissection | Coding Instruction 1 edited. | Deleted 'Lymph in data item name: Regional Nodes Examined |
| 183 | Section VII: First Course of Therapy | Date of Regional Lymph Node Dissection | Coding Instruction 2 revised. | 2. Record the date of the regional lymph node dissection in this data item and record the date of the sentinel lymph node biopsy procedure in the Date of Sentinel Lymph Node Biopsy data item [NAACCR Item #832] for **breast and cutaneous melanoma cases** whena. Both a sentinel lymph node biopsy procedure and a separate regional lymph node dissection procedure are performed ORb. A sentinel lymph node biopsy is performed in the same procedure as the regional lymph node dissection. In this case, the **dates should be the same.** |
| 183 | Section VII: First Course of Therapy | Date of Regional Lymph Node Dissection | Coding Instruction 3 revised. | 3. Record the date of the regional lymph node dissection in this data item for **all other cases** (in addition to breast and cutaneous melanoma cases) a. If a sentinel lymph node biopsy procedure is also performed, record the procedure in the Date of Sentinel Lymph Node Biopsy data item [NAACCR Item #832]. i. If the sentinel lymph node biopsy is performed in the same procedure as the regional lymph node dissection, the **dates should be the same** |
| 185 | Section VII: First Course of Therapy | Regional Nodes Positive | Coding Instruction 1.a edited. | Removed the year 2018 from EOD Regional Nodes: a. Include lymph nodes that are regional in the current AJCC Staging Manual or EOD Regional Nodes |
| 185 | Section VII: First Course of Therapy | Regional Nodes Positive | Coding Instruction 2 revised. | 2. **This data item is based on pathological information only**, including autopsy. This data item is to be recorded regardless of whether the patient received neoadjuvant (preoperative) treatment. Information from the autopsy may be used to code Regional Nodes Positive. Use text fields to explain the situation. |

SEER Program Coding and Staging Manual 2022 - Summary of Changes
This table lists the changes in the 2022 manual by page number.

| Page | Section | Data Item | Change | Notes/Comments |
|------|---------|-----------|--------|----------------|
| 187 | Section VII: First Course of Therapy | Regional Nodes Positive | Coding Instruction 11.b edited and 11.e and 11.f added. | 1.  Use code **99** for<br>a. Any case coded to primary site C420, C421, C423, C424, C589, C700-C709, C710-C729, C751-C753, C761-C768, C770-C779, or C809<br>b. Lymphoma  00790<br>c. Lymphoma-CLL/SLL  00795<br>d. Plasma Cell Disorders (excluding 9734/3)  00822<br>e. HemeRetic 00830 (excluding primary sites C420, C421, C423, C424)<br>f. Ill-Defined/Other 99999<br>g. Cases with no information about positive regional lymph nodes |
| 188 | Section VII: First Course of Therapy | Regional Nodes Examined | Coding Instruction 2 revised. | 2. **This data item is based on pathologic information only**, including autopsy. This data item is to be recorded regardless of whether the patient received neoadjuvant (preoperative) treatment. Information from the autopsy may be used to code Regional Nodes Examined. Use text fields to explain the situation. |
| 189 | Section VII: First Course of Therapy | Regional Nodes Examined | Coding Instruction 4.c revised. | Removed the word 'positive' before aspiration:<br>Include the node in the count of Regional Nodes Examined when the aspiration or core biopsy is from a node in a different node region |
| 190 | Section VII: First Course of Therapy | Regional Nodes Examined | Coding Instruction 12.b edited and 12.e and 12.f added. | 12.  Use code **99** for<br>a. Any case coded to primary site C420, C421, C423-C424, C589, C700-C709, C710-C729, C751-C753, C761-C768, C770-C779, or C809<br>b. Lymphoma  00790<br>c. Lymphoma-CLL/SLL  00795<br>d. Plasma Cell Disorders (excluding 9734/3)  00822<br>e. HemeRetic 00830 (excluding primary sites C420, C421, C423, C424)<br>f. Ill-Defined/Other 99999<br>g. Cases with no information about the examination of regional lymph nodes |
| 191 | Section VII: First Course of Therapy | Surgical Procedure of Other Site | Coding Instruction 3 and example added. | 3. For this data item, do not include organs beyond the primary site that are included in the Surgery of Primary Site codes.<br>*Example:* A hemicolectomy including removal of the small bowel. Surgery of Primary Site code 41 for colon includes resection of contiguous organ such as small bowel or bladder. Do not code removal of small bowel or bladder performed with a subtotal colectomy/hemicolectomy in Surgical Procedure of Other Site. |

This table lists the changes in the 2022 manual by page number.

| Page | Section | Data Item | Change | Notes/Comments |
|---|---|---|---|---|
| 192 | Section VII: First Course of Therapy | Surgical Procedure of Other Site | Coding Instructions 7 and 8 edited. | Removed 2018 from EOD; these instructions were previously numbered 6 and 7. |
| 193 | Section VII: First Course of Therapy | Reason for No Surgery of Primary Site | Code 2 Description revised. | Surgery of the primary site was not recommended/performed because it was contraindicated due to patient risk factors (comorbid conditions, advanced age, progression of tumor prior to planned surgery, etc.) |
| 194 | Section VII: First Course of Therapy | Reason for No Surgery of Primary Site | Coding Instruction 3.b and example added. | b. Assign code 2 when surgery of the primary site was contraindicated due to factors including, but not limited to, comorbid conditions, advanced age, and progression of tumor prior to planned surgery.*Example:* The patient with metastatic cancer of the right kidney to the lung has a history of prior nephrectomy of the left kidney with a current history of congestive heart disease and smoking.  The patient is considered a surgical risk. |
| 195 | Section VII: First Course of Therapy | Reason for No Surgery of Primary Site | Coding Instruction 3.d note edited. | Changed data item name in example: Reason for No Surgery of Primary Site |
| 229 | Section VII: First Course of Therapy | Neoadjuvant Therapy | Introductory text revised. | Revised third paragraph: For the purposes of this data item, neoadjuvant therapy is defined as systemic treatment (chemotherapy, endocrine/hormone therapy, targeted therapy, immunotherapy, or biological therapy) and/or radiation therapy before intended or performed surgical resection to improve local therapy and long-term outcomes during first course of treatment. |
| 231 | Section VII: First Course of Therapy | Neoadjuvant Therapy | Coding guidelines revised. | Added bullets to list of **criteria for neoadjuvant therapy**: •Neoadjuvant therapy data items are coded based on treatment/procedures that occur during first course of therapy. • Neoadjuvant therapy may be given as part of a clinical trial |
| 236 | Section VII: First Course of Therapy | Neoadjuvant Therapy-- Clinical Response | Coding Instruction 9.a note edited. | Changed 'as' to 'to': *Note:* Neoadjuvant Therapy data item [NAACCR #1632] coded to 1. |

SEER Program Coding and Staging Manual 2022 - Summary of Changes
This table lists the changes in the 2022 manual by page number.

| Page | Section | Data Item | Change | Notes/Comments |
|---|---|---|---|---|
| 237 | Section VII: First Course of Therapy | Neoadjuvant Therapy-- Clinical Response | Coding Instruction 10 note revised and examples added. | Added 'or 2' to coding instruction 10 note: *Note:* Neoadjuvant Therapy data item [NAACCR #1632] to 1 or 2.<br><br>Added examples:<br>*Example 2:* Patient starts neoadjuvant chemotherapy; however, patient expired after one cycle of chemotherapy.<br><br>*Example 3:* Patient starts neoadjuvant chemotherapy; however, due to rapid reporting of the case, the information is not yet available.  The code should be revised after treatment is completed. |
| 238 | Section VII: First Course of Therapy | Neoadjuvant Therapy-- Treatment Effect | Notes added. | Added notes below code table:*Note 1:* Code 0 indicates a patient did not receive any neoadjuvant treatment or received only a short course of hormone therapy that was not part of a clinical trial.  If hormone therapy is given as part of a clinical trial, it is coded as neoadjuvant treatment and not coded 0 for treatment effect.*Note 2:* Code 7 includes patients who complete or start neoadjuvant treatment and expire before surgical treatment.*Note 4:* Code 9 includes patients who start treatment and treatment effect information is not available at the time of reporting, such as with rapid case reporting.  Revise the code after treatment is completed. |
| 246 | Section VIII: Follow Up Information | Date of Last Cancer (Tumor) Status | Data item added. | See manual. |
| 247 | Section VIII: Follow Up Information | Date of Last Cancer (Tumor) Status Flag | Data item added. | See manual. |
| 248 | Section VIII: Follow Up Information | Cancer Status | Data item added. | See manual. |
| 249 | Section VIII: Follow Up Information | Recurrence Date--1st | Data item added. | See manual. |

SEER Program Coding and Staging Manual 2022 - Summary of Changes
This table lists the changes in the 2022 manual by page number.

| Page | Section | Data Item | Change | Notes/Comments |
|------|---------|-----------|--------|----------------|
| 252 | Section VIII: Follow Up Information | Recurrence Date--1st Flag | Data item added. | See manual. |
| 253 | Section VIII: Follow Up Information | Recurrence Type--1st | Data item added. | See manual. |
| | Appendix A | County Codes | Registries/county codes added. | Added counties and county codes for SEER registries that were added to the 2022 SEER Manual SEER Participant list. |
| | Appendix A | County Codes | Counties updated | Corrected county names for Arkansas. |
| | Appendix C: Site Specific Coding Modules | Coding Guidelines: Breast | Text added. | Added under Coding Subsites: Generally, codes C502 - C505 are preferred over C501. C501 is preferred over C508. Apply these general guidelines when there is no other way to determine the subsite using the available medical documentation. |
| | Appendix C: Site Specific Coding Modules | Coding Guidelines: Kidney | Text added. | Added section: Primary Site Transitional / urothelial cell carcinoma originates in the urethra, bladder, ureters, and renal pelvis. Code the primary site to renal pelvis (C659) when transitional / urothelial cell carcinoma originates in the "kidney." |
| | Appendix C: Site Specific Coding Modules | Coding Guidelines: Lung | Text added. | Added to Primary Site C349: Infrahilar area of lung, NOS |

This table lists the changes in the 2022 manual by page number.

| Page | Section | Data Item | Change | Notes/Comments |
|---|---|---|---|---|
| | Appendix C: Site Specific Coding Modules | Coding Guidelines: Melanoma | Text added. | Added section:<br>Primary Site<br>Assign C449 for melanoma when the primary site is unknown and there is no information suggesting that the melanoma originated in a non-skin site. Assign C809 when the site of origin is unknown and there is some indication that the primary site of the melanoma is not skin |
| | Appendix C: Site Specific Coding Modules | Coding Guidelines: Renal Pelvis and Ureter | Text added. | Added section:<br>Primary Site<br>Transitional / urothelial cell carcinoma originates in the urethra, bladder, ureters, and renal pelvis. Code the primary site to renal pelvis (C659) when transitional / urothelial cell carcinoma originates in the "kidney." |
| | Appendix C: Site Specific Coding Modules | Coding Guidelines: Urethra | Text added. | Added section:Primary SiteC680 is the only ICD-O-3 code available for urethra. Assign C680 for penile urethra and for prostatic urethra.Transitional / urothelial cell carcinoma originates in the urethra, bladder, ureters, and renal pelvis. Code the primary site to urethra (C680) when transitional / urothelial cell carcinoma involves the prostate and the urethra. |
| | Appendix C: Site Specific Coding Modules | Surgery Codes: Anus | Codes deleted. | Removed codes 11 Photodynamic therapy (PDT), 13 Cryosurgery, 14 Laser, 21 Photodynamic therapy (PDT), 23 Cryosurgery, 24 Laser ablation, 25 Laser excision. Updated text following the Local tumor destruction codes: No specimen sent to pathology from surgical events 10, 12, and 15. |
| | Appendix C: Site Specific Coding Modules | Surgery Codes: Colon | Codes deleted. | Removed codes 11 Photodynamic therapy (PDT), 13 Cryosurgery, 14 Laser, 21 Photodynamic therapy (PDT), 23 Cryosurgery, 24 Laser ablation, 25 Laser excision. Updated text following the Local tumor destruction codes: No specimen sent to pathology from surgical events 10 and 12.<br>Revised SEER Note:   [*SEER Note:* Code 22 above combines 20 Local tumor excision, 27 Excisional biopsy, 26 Polypectomy, NOS, 28 Polypectomy-endoscopic, or 29 Polypectomy-surgical excision WITH 22 Electrocautery] |

SEER Program Coding and Staging Manual 2022 - Summary of Changes
This table lists the changes in the 2022 manual by page number.

| Page | Section | Data Item | Change | Notes/Comments |
|------|---------|-----------|--------|----------------|
| | Appendix C: Site Specific Coding Modules | Surgery Codes: Rectosigmoid | Codes deleted. | Removed codes 11 Photodynamic therapy (PDT), 13 Cryosurgery, 14 Laser ablation, 21 Photodynamic therapy (PDT), 23 Cryosurgery, 24 Laser ablation, 25 Laser excision. Updated text following the Local tumor destruction codes: No specimen sent to pathology from surgical events 10 and 12. |
| | Appendix C: Site Specific Coding Modules | Surgery Codes: Rectum | Codes deleted; code revised. | Removed codes 11 Photodynamic therapy (PDT), 13 Cryosurgery, 14 Laser, 21 Photodynamic therapy (PDT), 23 Cryosurgery, 24 Laser ablation, 25 Laser excision; revised code 30: Segmental resection; partial proctectomy, NOS.  Updated text following the Local tumor destruction codes: No specimen sent to pathology from surgical events 10 and 12. |
| | Appendix C: Site Specific Coding Modules | Surgery Codes: Skin | Note added. | *[SEER Note:* You may take margin information from the operative report if it is missing from the pathology report when assigning the surgery codes for skin.  This applies to any skin malignancy for which the skin surgery codes apply.*Exception:* Do not apply this to surgery codes 45-47 where specific instructions about microscopic confirmation are included.] |
| | Appendix C: Site Specific Coding Modules | Surgery Codes: All surgery codes | Header information deleted. | Removed the histology code exceptions in the header of all of the surgery code documents. |
| | Appendix C: Site Specific Coding Modules | Neoadjuvant Therapy Treatment Effect Site Specific Codes: all | Coding instruction 1 Note updated. | Revised the note on all Neoadjuvant Therapy--Treatment Effect coding guidelines: *Note:* Neoadjuvant Therapy data item [NAACCR # 1632] coded to 0 or 3. |

SEER Program Coding and Staging Manual 2022 - Summary of Changes
This table lists the changes in the 2022 manual by page number.

| Page | Section | Data Item | Change | Notes/Comments |
|---|---|---|---|---|
| | Appendix C: Site Specific Coding Modules | Neoadjuvant Therapy Treatment Effect Site-Specific Codes: All Other Schemas | Code Descriptions edited. | Edited code descriptions 2 and 3 to add a carriage return (enter):<br>Code 2<br>Near complete pathological response<br>Present: Single cells or rare small groups of invasive cancer cells<br>Code 3<br>Partial or minimal pathological response<br>Present: Residual invasive cancer with evident tumor regression, but more than single cells or rare small groups of cancer cells |
| | Appendix C: Site Specific Coding Modules | Neoadjuvant Therapy Treatment Effect Site Specific Codes: Colon and Rectum, Esophagus, Stomach, Anus, Pancreas | Code Description revised. | Corrected description of Code 0:<br>Neoadjuvant therapy not given/no known presurgical therapy |
| | Appendix C: Site Specific Coding Modules | Neoadjuvant Therapy Treatment Effect Site Specific Codes: Pleural Mesothelioma | New site specific document added. | Added Appendix C, Neoadjuvant Therapy Treatment Effect Site-Specific Codes for Pleural Mesothelioma.  See Appendix C. |
| | Appendix C: Site Specific Coding Modules | Neoadjuvant Therapy Treatment Effect Site-Specific Codes: Prostate | Coding Instruction 1.a example and exception added. | *Example:* Patient received a short course of hormone therapy and it is not part of a clinical trial.<br>*Exception:*  If hormone therapy is given as part of a clinical trial, this is coded as neoadjuvant therapy and would not be coded as 0 for treatment effect. |

| Page | Section | Data Item | Change | Notes/Comments |
|---|---|---|---|---|
| | Appendix C: Site Specific Coding Modules | Neoadjuvant Therapy Treatment Effect Site-Specific Codes: Prostate | Coding Instruction 4.a note and example added. | ***Note:*** If hormone therapy is given as part of a clinical trial, this is considered neoadjuvant therapy.<br>***Example:*** Patient has localized prostate cancer and is part of a clinical trial.  Three hormonal agents along with two ancillary agents were administered for 3 months, followed by radical prostatectomy that showed treatment effect. |
| | Appendix E1 | Reportable Examples | Example 21 added. | Report low-grade appendiceal mucinous neoplasm (LAMN).<br>LAMN is assigned a behavior of /2 or /3 making it reportable.  LAMNs are slow-growing neoplasms that have the potential for peritoneal spread and can result in patient death. LAMNs demonstrate an interesting biology in that they do not have hematogenous dissemination risk, but risk for appendiceal perforation, which can result in peritoneal dissemination, repeated recurrences after surgery and even death. |
| | Appendix E2 | Non-Reportable Examples | Example deleted. | Deleted former #2:<br>Anal intraepithelial neoplasia (AIN) II-III, AIN II/III; Vaginal intraepithelial neoplasia (VAIN) II-III, VAIN II/III;<br>Vulvar intraepithelial neoplasia (VIN) II-III, VIN II/III, etc.<br><br>Subsequent items renumbered. |
| | Appendix E2 | Non-Reportable Examples | Example 30 revised. | Rathke cleft cyst, also called pars intermedia cyst of the parotid gland, and is not reportable; whereas, Rathke pouch tumor is reportable. |
| | Appendix E2 | Non-Reportable Examples | Example 31 added. | Colon atypical hyperplasia |
| | Appendix E2 | Non-Reportable Examples | Example 32 added. | High grade dysplasia in colorectal and esophageal primary sites |